In vivo binding, pharmacokinetics and metabolism of the selective M2 muscarinic antagonists [3H]AF-DX 116 and [3H]AF-DX 384 in the anesthetized rat

Nuclear Medicine and Biology

Volumn 23, Issue 2, 1996, Pages 173-179

  Mickala, Patrick ^a   Boutin, Hervé ^a   Bellanger, Cécile ^a   Chevalier, Cyril ^a   MacKenzie, Eric T ^a   Dauphin, François ^a  

^a UNIVERSITÉ DE CAEN   (France)

Author keywords

AF DX 116; AF DX 384; In vivo binding; M2 receptor antagonist; Muscarinic receptors; Rat

Indexed keywords

MUSCARINIC RECEPTOR; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; OTENZEPAD; TRITIUM;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG METABOLISM; HEART; PHARMACOKINETICS; RAT;

ANESTHESIA; ANIMALS; BRAIN; CHROMATOGRAPHY, THIN LAYER; HALF-LIFE; MALE; MUSCARINIC ANTAGONISTS; PARASYMPATHOLYTICS; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0029918517     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(95)02015-2     Document Type: Article

References (40)

1. Araujo D. M., Lapchak P. A., Robitaille Y., Gautier S. and Quirion R. (1988) Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J. Neurochem. 50, 1914-1923.
2. Aubert I., Araujo D. M., Cécyre D., Robitaille Y., Gauthier S. and Quirion R. (1992) Comparative alterations of nicotinic and muscarinic biding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58, 529-541.
3. Bonner T. I. (1989) The molecular basis of muscarinic receptor density. Trends Neurosci. 12, 148-151.
4. Bonner T. I., Young A. C., Brann M. R. and Buckley N. J. (1988) Cloning and expression of the human and rat M5 muscarinic acetylcholine receptor genes. Neuron 1, 403-410.
5. Buckley N.J., Bonner T. I., Buckley C. M. and Brann M. R. (1989) Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol. 35, 469-476.
6. Dauphin F., Bellanger C., Mickala P., Duval D. and MacKenzie E. T. (1993) Rat in vivo binding and pharmacokinetic profile of [H-3]-AF-DX 116, a selective M2 muscarinic receptor antagonist. J. Nucl. Med. 34.
7. De Angelis M. M., Hayes R. L. and Lyeth B. G. (1994) Traumatic brain injury causes a decrease in M2 muscarinic cholinergic receptor binding in the rat brain. Brain Res. 653, 39-44.
8. Decker M. W. and McGaugh J. L. (1991) The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7, 151-168.
9. 11C-methyl]-benztropine. Synapse 5, 213-223.
10. 3 receptors. J. Pharmacol Exp. Ther. 242, 257-262.
11. Dörje F., Wess J., Lambrecht G., Tacke R., Mutschler E. and Brann M. R. (1991) Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256, 727-733.
12. Elenkov I. J. and Vizi E. S. (1991) Presynaptic modulation of release of noradrenaline from sympathetic nerve terminals in the rat spleen. Neuropharmacology 30, 1319-1324.
13. 3H]AF-DX 384. Biochem. Pharmacol. 40, 1674-1676.
14. 11C]scopolamine and positron emission tomography. J. Cereb. Blood Flow Metab. 12, 147-154.
15. Gies J. P., Bertrand C., Vanderheyden P., Waeldele F., Dumont P., Pauli G. and Landry Y. (1989) Characterization of muscarinic receptors in human, guinea pig and rat lung. J. Pharmacol. Exp. Ther. 250, 309-315.
16. Hoss W., Messer W. S. Jr., Monsma F. J. Jr., Miller M. D., Ellerbrock B. R., Scranton T., Ghodsi-Hovsepian S., Price M. A., Balan S., Mazloum Z. and Bohnett M. (1990) Biochemical and behavioral evidence for muscarinic autoreceptors in the CNS. Brain Res. 517, 195-201.
17. 11C]Tropanyl benzilate-binding to muscarinic cholinergic receptors: Methodology and kinetic modeling alternatives. J. Cereb. Blood Flow Metab. 14, 85-99.
18. Korth M. and Kühlkamp V. (1987) Muscarinic receptors mediate negative and positive inotropic effects in mammalian ventricular myocardium: Differentiation by agonists. Br. J. Pharmacol. 90, 81-90.
19. 3H]AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. Brain Res. 496, 285-294.
20. 2 receptors for positron emission tomography studies. In Tenth International Symposium on Radiopharmaceutical Chemistry, Kyoto, pp. 425-426.
21. Lee N. H. and El-Fakahany E. E. (1991). Allosteric interactions at m1, m2 and m3 muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256, 468-479.
22. Mak J. C. W. and Barnes P. J. (1989) Muscarinic receptor subtypes in human and guinea pig lung. Eur. J. Pharmacol. 164, 223-230.
23. Mash D. C., Flynn D. D. and Potter L. T. (1985) Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228, 1115-1117.
24. Mash D. C. and Potter L. T. (1986) Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience 19, 551-564.
25. 3H]AF-DX 384 in the rat. Can. J. Physiol. Pharmacol. 72(Suppl. 1), 375, P13.9.13.
26. 3H]AF-DX 384 to cloned and native muscarinic receptors. J. Pharmacol. Exp. Ther. 259, 601-607.
27. 11C]NMPB), a muscarinic acetylcholine receptor antagonist. Nucl. Med. Biol. 22, 13-17.
28. 123I]-4-iodolevetimide. J. Cereb. Blood Flow Metab. 12, 562-570.
29. Nilvebrant L. and Sparf B. (1988) Receptor binding profiles of some selective muscarinic antagonists. Eur. J. Pharmacol. 151, 83-96.
30. Nordberg A. (1992) Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 4, 303-328.
31. 2 receptor antagonist AF-DX 116 improves memory. Brain Res. 524, 72-76.
32. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, Sidney.
33. Peralta E. G., Ashkenazi A., Winslow J. W., Smith D. H., Ramachadran J. and Caron D. (1987) Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 6, 3923-3929.
34. Schulte B., Votz-Zang C., Mutschler E., Home C., Palm D., Wellstein A. and Pitschner H. F. (1991) AF-DX 116, a cardioselective muscarinic antagonist in humans: Pharmacodynamic and pharmacokinetic properties. Clin. Pharmacol. Ther. 50, 372-378.
35. Shida T., Tokunaga A., Kondo E., Ueda Y., Ohno K. Saika T., Kiyama H. and Tohyama M. (1993) Expression of muscarinic and nicotinic receptor mRNA in the salivary gland of rats: A study by in situ hybridization histochemistry. Mol. Brain Res. 17, 335-339.
36. Spencer D. G. Jr., Horváth E. and Traber J. (1986) Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: Relation to cholinergic nuclei and projections. Brain Res. 380, 59-68.
37. 11C]quinuclidinyl benzilate and positron emission tomography in baboons. Eur. J. Pharmacol. 213, 275-284.
38. 4) in rat forebrain. Mol. Pharmacol. 38, 267-273.
39. Wilkinson M., Horackova M. and Giles A. (1994) Reduction of ventricular M2 muscarinic receptors in cardiomyopathic hamsters (CHF 147) at the necrotic stage of the myopathy. Pflügers Arch. 426, 516-523.
40. Yamada S., Yamamura H. I. and Roeske W. R. (1982) Characterization of postsynaptic beta-adrenergic receptors and presynaptic muscarinic cholinergic receptors in the rat spleen. Life Sci. 31, 1161-1170.